Celltrion Secures Dominant Market Share in Asia Led by Autoimmune and Oncology Biosimilars
Celltrion is consolidating its leading market position across major Asian countries with its key autoimmune and oncology therapies.
Search results for "cell therapy"
Why Stage 3 Breast Cancer Doesn’t Always Mean Immediate Surgery
“Shouldn’t it be removed as soon as possible — even a day sooner?”This reaction is common among patients and their families following a cancer...
550 Days in Limbo: Groups Demand 100-Day Fast-Track Insurance Coverage for Breakthrough PAH Drug Winrevair
With national health insurance coverage for the new pulmonary arterial hypertension treatment Winrevair (active...
Suspected Pancreatic Cancer Once Meant a Two-Night Stay. Asan Medical Center Cuts It to One Day
When patients are told something looks abnormal in their pancreas, many begin worrying about hospital admission even...
VOYXACT Preserves Kidney Function for Two Years in Phase 3 IgA Nephropathy Trial
Otsuka Pharmaceutical’s VOYXACT (active ingredient: sibeprenlimab) demonstrated long-term kidney protection by...
Scalp-Injected RNA Hair Loss Drug Completes Phase 1b Dosing in Australia
OliX announced on August 4 that it has completed patient dosing in the Australian Phase 1b clinical trial for OLX104C...
Timing of Immune Cell Entry Dictates Anti-Cancer Defense in Hard-to-Treat Brain Tumors
Some immune cells surrounding a tumor actively attack it, while others create conditions that help it survive.
Prevention vs. Treatment: Why Cancer Therapy Demands a Completely Different Diet
What makes diabetes particularly dangerous is the risk of severe, systemic complications.
Novartis Halts Lu-NeoB Development After Early Clinical Data Fall Short
Novartis has discontinued the development of Lu-NeoB, an experimental cancer therapy designed to seek out tumor cells...
The Blood Cancer Decoy: Why Some Lymphoma Patients Stop Responding to Treatment
For patients diagnosed with aggressive blood cancers, receiving a proven targeted therapy offers a clear path toward a...